Article

Are young injection drug users ready and willing to participate in preventive HCV vaccine trials?

San Mateo County Health Systems, San Mateo, CA, USA.
Vaccine (Impact Factor: 3.49). 08/2010; 28(37):5947-51. DOI: 10.1016/j.vaccine.2010.07.006
Source: PubMed

ABSTRACT Trials to evaluate the efficacy of preventive HCV vaccines will need participation from high risk HCV seronegative injection drug users (IDUs). To guide trial planning, we assessed willingness of young IDU in San Francisco to participate in HCV vaccine efficacy trials and evaluate knowledge of vaccine trial concepts: placebo, randomization and blinding. During 2006 and 2007, a total of 67 participants completed the survey. A substantial proportion (88%) would definitely (44%) or probably (44%) be willing to participate in a randomized trial, but knowledge of vaccine trial concepts was low. Reported willingness to participate in an HCV vaccine trial decreased with increasing trial duration, with 67% of participants surveyed willing to participate in a trial of 1 year duration compared to 43% of participants willing to participate in a trial of 4 years duration. Willingness to enroll in HCV vaccine trials was higher in young IDU than reported by most at-risk populations in HIV vaccine trials. Educational strategies will be needed to ensure understanding of key concepts prior to implementing HCV vaccine trials.

Download full-text

Full-text

Available from: Ellen Stein, Aug 14, 2014
0 Followers
 · 
176 Views
  • Source
    • "Some who held contingent WTP also recognised time constraints as a barrier and requested further information about the level of commitment and travel time required for participation , as observed in a qualitative investigation of hypothetical WTP in HIV vaccine trials (Strauss et al., 2001). While not raised by our participants, trial duration has also been documented as a barrier to WTP in HCV VPS (Levy et al., 2010). Trial duration, in addition to flexibility in appointment times and days and travel time may be important factors to be negotiated during trial design in order to optimise enrolment and retention. "
    [Show abstract] [Hide abstract]
    ABSTRACT: A safe and efficacious vaccine may be the most efficient and cost-effective strategy for controlling the hepatitis C virus (HCV) epidemic among people who inject drugs (PWID) and several candidates are in development. However, little is known about the factors that influence willingness to participate (WTP) in candidate HCV vaccine trials among this group. HCV seronegative PWID recruited between 2008 and 2010 as part of a prospective observational cohort study in Sydney, Australia were asked whether they would be willing to participate in a future candidate hepatitis C vaccine trial and to provide reasons to explain their decision. Of 113 participants, 74% indicated WTP, 15% were unwilling to participate and 11% reported WTP that was contingent on vaccine characteristics and trial design issues. The most commonly reported motivator for hypothetical trial participation was altruism, followed by potential health benefits, financial remuneration, and knowledge gain. Barriers to hypothetical participation included fears about possible harms to health, such as concerns about vaccine safety, side effects, and acquiring HCV from the vaccine; other barriers included mistrust of biomedical research and time constraints. These results may be useful in designing strategies to enhance HCV vaccine trial recruitment and retention and have ethical implications for developing informed consent processes and standards of care.
    Drug and alcohol dependence 11/2011; 123(1-3):35-40. DOI:10.1016/j.drugalcdep.2011.10.009 · 3.28 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: People who inject drugs (PWID) are at high risk of HCV. Limited evidence of the effectiveness of prevention interventions and low uptake of treatment in this group highlight the need for increased investment in biomedical interventions, notably safe and efficacious vaccines. While several candidates are currently in development, field trials in PWID present challenges, including ethical issues associated with trial literacy, informed consent and standards of care. Significant biological and social factors and differences between HIV and HCV suggest that HCV warrants targeted vaccine preparedness research to lay the groundwork for successful implementation of future trials.
    Vaccine 10/2010; 28(45):7273-8. DOI:10.1016/j.vaccine.2010.08.085 · 3.49 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: In this article, we present a graphical user interface software for the litter decomposition and soil carbon model Yasso07 and an overview of the principles and formulae it is based on. The software can be used to test the model and use it in simple applications. Yasso07 is applicable to upland soils of different ecosystems worldwide, because it has been developed using data covering the global climate conditions and representing various ecosystem types. As input information, Yasso07 requires data on litter input to soil, climate conditions, and land-use change if any. The model predictions are given as probability densities representing the uncertainties in the parameter values of the model and those in the input data - the user interface calculates these densities using a built-in Monte Carlo simulation.
    Environmental Modelling and Software 11/2011; 26(11):1358-1362. DOI:10.1016/j.envsoft.2011.05.009 · 4.54 Impact Factor
Show more